Q3 EPS Forecast for Sangamo Therapeutics Lifted by Analyst

Sangamo Therapeutics, Inc. (NASDAQ:SGMO - Free Report) - Equities researchers at HC Wainwright boosted their Q3 2025 earnings per share (EPS) estimates for shares of Sangamo Therapeutics in a note issued to investors on Wednesday, May 14th. HC Wainwright analyst P. Trucchio now expects that the biopharmaceutical company will earn ($0.08) per share for the quarter, up from their prior estimate of ($0.11). HC Wainwright currently has a "Buy" rating and a $10.00 target price on the stock. The consensus estimate for Sangamo Therapeutics' current full-year earnings is ($0.46) per share. HC Wainwright also issued estimates for Sangamo Therapeutics' FY2025 earnings at ($0.17) EPS, FY2026 earnings at ($0.17) EPS and FY2027 earnings at ($0.04) EPS.

Sangamo Therapeutics (NASDAQ:SGMO - Get Free Report) last issued its earnings results on Monday, May 12th. The biopharmaceutical company reported ($0.14) earnings per share for the quarter, missing the consensus estimate of ($0.11) by ($0.03). The company had revenue of $6.44 million during the quarter, compared to analyst estimates of $7.90 million. Sangamo Therapeutics had a negative return on equity of 264.16% and a negative net margin of 257.87%.

A number of other research firms have also issued reports on SGMO. Truist Financial reduced their target price on shares of Sangamo Therapeutics from $7.00 to $5.00 and set a "buy" rating for the company in a research note on Thursday, January 23rd. Royal Bank of Canada reissued a "sector perform" rating and set a $2.00 target price on shares of Sangamo Therapeutics in a research note on Tuesday, March 18th. Barclays reduced their target price on shares of Sangamo Therapeutics from $9.00 to $5.00 and set an "overweight" rating for the company in a research note on Wednesday, May 14th. Finally, Wall Street Zen began coverage on shares of Sangamo Therapeutics in a research report on Thursday. They set a "hold" rating on the stock. Three research analysts have rated the stock with a hold rating and four have given a buy rating to the company. According to MarketBeat, the company has a consensus rating of "Moderate Buy" and an average target price of $4.50.

Sangamo Therapeutics Price Performance

Shares of SGMO stock traded down $0.02 during trading hours on Monday, reaching $0.47. The stock had a trading volume of 2,505,854 shares, compared to its average volume of 8,743,457. The firm has a 50-day simple moving average of $0.69 and a 200-day simple moving average of $1.27. The firm has a market capitalization of $110.36 million, a PE ratio of -0.63 and a beta of 1.46. Sangamo Therapeutics has a twelve month low of $0.30 and a twelve month high of $3.18.

Institutional Trading of Sangamo Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the business. Wealth Enhancement Advisory Services LLC raised its holdings in shares of Sangamo Therapeutics by 12.4% in the 4th quarter. Wealth Enhancement Advisory Services LLC now owns 122,463 shares of the biopharmaceutical company's stock worth $125,000 after purchasing an additional 13,518 shares in the last quarter. LPL Financial LLC raised its holdings in shares of Sangamo Therapeutics by 113.5% during the fourth quarter. LPL Financial LLC now owns 31,031 shares of the biopharmaceutical company's stock valued at $32,000 after acquiring an additional 16,498 shares during the period. Northern Trust Corp raised its holdings in shares of Sangamo Therapeutics by 4.5% during the fourth quarter. Northern Trust Corp now owns 398,289 shares of the biopharmaceutical company's stock valued at $406,000 after acquiring an additional 17,049 shares during the period. JPMorgan Chase & Co. raised its holdings in shares of Sangamo Therapeutics by 679.5% during the fourth quarter. JPMorgan Chase & Co. now owns 25,000 shares of the biopharmaceutical company's stock valued at $26,000 after acquiring an additional 21,793 shares during the period. Finally, E Fund Management Co. Ltd. acquired a new stake in shares of Sangamo Therapeutics during the fourth quarter valued at approximately $25,000. 56.93% of the stock is currently owned by institutional investors.

Sangamo Therapeutics Company Profile

Sangamo Therapeutics, Inc, a clinical-stage genomic medicine company, focuses on translating science into medicines that transform the lives of patients and families afflicted with serious diseases in the United States. The company's clinical-stage product candidates are ST-920, a gene therapy product candidate, which is in Phase 1/2 clinical study for the treatment of Fabry disease; TX200, a chimeric antigen receptor engineered regulatory T cell (CAR-Treg) therapy product candidate that is in Phase 1/2 clinical study for the prevention of immune-mediated rejection in HLA-A2 mismatched kidney transplantation; SB-525, a gene therapy product candidate, which is in Phase 3 clinical trial for the treatment of moderately severe to severe hemophilia A; BIVV003, a zinc finger nuclease gene-edited cell therapy product candidate that is in Phase 1/2 PRECIZN-1 clinical study for the treatment of sickle cell disease.